NCM·Healthcare·$402M·#20 / 520 in Healthcare
AKBA Akebia Therapeutics, Inc.
77SOLID
CATEGORY BREAKDOWN
GROWTH76
QUALITY99
STABILITY67
VALUATION97
GOVERNANCE50
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
+47.5%
76
> 50% strong
Gross Margin
Revenue retained after direct costs
83.3%
100
> 50% strong
Cash Runway
Months of cash at current burn rate
999 months
100
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
158.8%
0
< 25% strong
Price / Sales
Market cap relative to trailing revenue
1.7x
97
< 3x strong
Rule of 40
Growth rate plus operating margin
57
97
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
4.0%
32
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+2.5%
85
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE AKBA WITH…
OR QUICK-COMPARE SECTOR PEERS
RELATED RESEARCH
2 Best Small-Cap Mental Health Tech & Psychedelic Therapeutics Stocks — May 2026May 2, 2026SCORE ALERT
Get notified when AKBA's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.